|
Thiazolidinediones: glucose-lowering drugs |
|---|---|
| รหัสดีโอไอ | |
| Creator | Somlak Chuengsamarn |
| Title | Thiazolidinediones: glucose-lowering drugs |
| Publisher | Faculty of Medicine,Srinakharinwirot University |
| Publication Year | 2548 |
| Journal Title | Journal of Medicine and Health Sciences |
| Journal Vol. | 12 |
| Journal No. | 2 |
| Page no. | 14-27 |
| Keyword | Thiazolidinediones / insulin resistance / Treatment |
| ISSN | 0859-3319 |
| Abstract | Thiazolidinediones are glucose-lowering drugs in the group of insulin sensitizers. Their mechanism ofaction is an increase insulin sensitivity, which had to reduce of high level of insulin in patients with insulinresistanttype 2 diabetes. Addition to lower blood sugar level, thiazolidinediones also affect many humanmetabolism because these drugs are selective ligands of the nuclear transcription factor peroxisome-proliferatoractivatedreceptor ? (PPAR-?), a nuclear receptor which regulate gene transcription and expression in cells andtissues, like adipose tissues, pancreatic beta cells, vascular endothelium and macrophage. Therefore, they haveeffect on non-glycemic controls such as differentiation of adipose tissues, lowering of triglyceride and secretingof adipokines. Nowadays, thiazolidinediones are the only oral hypoglycemic drugs, which are reducing of riskof event of coronary heart disease. The purpose of this article is to summarize the mechanism of action ofthiazolidinediones, effects of glucose concentrations and the other effects of non- glycemic controls byevidence-base study in the human. |
